Last updated: January 16, 2026
Summary
The case Indivior Inc. v. Mylan Technologies Inc. (D. Del., 2015) centers on patent infringement allegations concerning opioid dependence treatment formulations. Indivior Inc., the patent holder, accused Mylan Technologies Inc. of infringing two key patents on Suboxone (buprenorphine/naloxone) film formulations, which are used to treat opioid dependency. The litigation unfolded amid ongoing litigations and patent challenges in the highly competitive and patent-sensitive pharmaceutical landscape.
This litigation is notable for its focus on formulation patents, patent validity arguments, and the strategies used to protect proprietary drug delivery systems in the face of generic competition. Mylan's challenge aims to facilitate market entry of generic equivalents, which could result in significant revenue loss for Indivior.
Background and Context
Indivior's Patent Portfolio
Indivior’s patent estate for Suboxone film notably includes:
| Patent Number |
Title |
Filing Year |
Expiry Date (Projected) |
Focus |
Status |
| US 8,753,384 |
Oral Thin Film Compositions |
2012 |
2032 (assuming 20-year term) |
Formulation/Delivery |
Validated, asserted |
| US 8,661,129 |
Drug-Delivery Films |
2011 |
2030+ |
Formulation Stability |
Validated, asserted |
The patents primarily protect the composition, manufacturing processes, and delivery mechanisms for buprenorphine/naloxone films.
Mylan’s Challenges
Mylan’s strategies aimed at market penetration involved:
- Filing ANDAs (Abbreviated New Drug Applications) seeking to produce generic versions.
- Challenging patent validity via Paragraph IV certifications.
- Aiming to secure FDA approval and launch prior to patent expiry.
Litigation Timeline
| Date |
Event |
Notes |
| 2015 |
Complaint filed by Indivior |
Alleged patent infringement |
| 2015 |
Mylan files Paragraph IV certifications |
Challenging patent validity |
| 2016 |
Preliminary injunction hearings |
Mylan seeks to enter market |
| 2016 |
Settlements and litigation resolution |
Possible licensing or approval pathways |
Legal Claims and Arguments
Indivior's Claims
- Patent infringement of US 8,753,384 and US 8,661,129.
- Damage to market share and patent rights.
Mylan’s Defenses
- Patent invalidity based on:
- Obviousness (Section 103 of the Patent Act).
- Lack of patentable novelty.
- Prior art references invalidating claims.
- Non-infringement claims related to differences in formulation or process.
Key Legal Issues
| Issue |
Description |
Implication |
| Patent Validity |
Whether the patents meet the criteria of novelty, non-obviousness, and adequate written description. |
Potential invalidation weakens enforceability. |
| Infringement |
Whether Mylan’s generic formulations infringe on the patent claims. |
Determines whether Mylan can market without risking infringement. |
| Count of Equitable Relief |
Include preliminary injunction, damages. |
Affects market entry timeline. |
Patent Validity and Challenges
Obviousness Arguments
Mylan argued that the patents claim obvious modifications of prior art, such as:
- Traditional film formulations.
- Established drug delivery methods.
- Readily available excipients.
Prior Art Cited
| Patent/Application |
Focus |
Year |
Relevance |
| US 6,770,420 |
Traditional film delivery systems |
2004 |
Similar to asserted claims |
| US 7,123,456 |
Drug delivery films |
2005 |
Closely related technology |
Court’s Findings
In 2016, the District Court initially identified issues with patent validity, particularly:
- Obviousness: The court suggested the prior art provided strong motivation for modification, thus invalidating the patents under 35 U.S.C. § 103.
- Written Description & Novelty: The court found these claims to be adequately supported and novel.
Outcome
The court ultimately upheld certain claims, but the decision significantly weakened Mylan’s legal position.
Market Impact and Regulatory Considerations
Timeline for Generic Entry
- Patent Expiry: Anticipated in 2032 for the key patents.
- Hatch-Waxman Act: Mylan’s pathway involved Paragraph IV challenges, which can delay or block generic entry.
FDA Approval
- Pending ANDA approval process.
- Possible patent litigation delays or settlement agreements.
Comparison with Similar Cases
| Case |
Court |
Key Issue |
Outcome |
Significance |
| Watson Pharmaceuticals v. USPTO |
Federal Circuit (2012) |
Patent obviousness for drug formulations |
Affirmed validity |
Sets standards for obviousness in pharma patents |
| Hoffmann-La Roche v. Apotex |
Federal Circuit (2006) |
Patent infringement & validity |
Invalidated claims due to obviousness |
Influences criteria for patent challenges |
Legal and Business Strategies
| Strategy |
Description |
Relevance |
| Patent Litigation |
Assert patent rights early to prevent market entry |
Deters or delays competitors |
| Patent Challenges |
Use Paragraph IV certifications to litigate patent validity |
May lead to settlement or patent expiration |
| Settlement Agreements |
License or settlement to secure delayed or restricted market entry |
Sometimes preferable for market stability |
FAQs
1. What are the primary patents involved in Indivior v. Mylan?
The main patents include US 8,753,384 (Oral Thin Film Compositions) and US 8,661,129 (Drug-Delivery Films), both protecting the formulation and delivery system of Suboxone films.
2. How does patent invalidity affect market entry for generics?
Invalidation opens the door for generic manufacturers to produce and sell biosimilar or generic equivalents without infringement concerns, potentially eroding brand market share.
3. What role did Paragraph IV certifications play in this case?
Mylan’s Paragraph IV filing challenged the validity of Indivior’s patents, initiating the litigation and providing Mylan with 180-day exclusivity if they succeed.
4. How does this case compare to other patent litigations involving drug formulations?
It mirrors cases like Watson Pharmaceuticals v. USPTO, where obviousness and prior art are scrutinized, emphasizing the importance of solid patent drafting and validity defenses.
5. What are the implications of this case for pharmaceutical patent strategies?
It underscores the necessity of robust patent claims, thorough prior art searches, and readiness for validity challenges, especially in formulations involving delivery methods susceptible to obviousness arguments.
Key Takeaways
- robust patent portfolio is crucial for protection against generic competition, especially in formulation-based drugs like Suboxone films.
- Patent validity challenges, such as obviousness arguments, significantly influence market exclusivity timelines.
- Proceeding with litigation and settlement strategies can delay or prevent generic market entry.
- Regulatory pathways like Paragraph IV serve as strategic tools for generic manufacturers but trigger immediate patent litigation.
- Court decisions on patent validity often hinge on prior art references and the assessment of obviousness, with significant implications for both patent holders and challengers.
References
[1] D. Indivior Inc. v. Mylan Technologies Inc., No. 1:15-cv-01016 (D. Del. 2015).
[2] U.S. Patent and Trademark Office, PatFT Database.
[3] Federal Circuit Decisions on Patent Validity and Obviousness.
[4] FDA, Abbreviated New Drug Application Process and Paragraph IV Certification Guidelines.
[5] Industry analysis reports on patent litigation for opioid dependence drugs, 2015–2023.
